Moderna Stock Falls on Vaccine Revenue Concerns

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to$51, citing ongoing vaccine revenue challenges.If these pre-market losses hold, Moderna stock could erase part of its 8.1% year-to-date lead and deepen its 57.1% year-over-year loss. The equity may also slip below a critical technical level -- its 20-day moving average -- which could pressure ...